JP2001500893A - インスリンｃ―ペプチド - Google Patents

インスリンｃ―ペプチド

Info

Publication number
JP2001500893A
JP2001500893A JP10515410A JP51541098A JP2001500893A JP 2001500893 A JP2001500893 A JP 2001500893A JP 10515410 A JP10515410 A JP 10515410A JP 51541098 A JP51541098 A JP 51541098A JP 2001500893 A JP2001500893 A JP 2001500893A
Authority
JP
Japan
Prior art keywords
peptide
fragment
insulin
seq
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10515410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001500893A5 (enExample
Inventor
ヴァーレン，ヨーン
ヨーハンソン，ブー―レンナート
イェーンヴァル，ハンス
Original Assignee
クリエイティヴ・ペプティドス・スウェーデン・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリエイティヴ・ペプティドス・スウェーデン・アクチエボラーグ filed Critical クリエイティヴ・ペプティドス・スウェーデン・アクチエボラーグ
Publication of JP2001500893A publication Critical patent/JP2001500893A/ja
Publication of JP2001500893A5 publication Critical patent/JP2001500893A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP10515410A 1996-09-27 1997-09-26 インスリンｃ―ペプチド Ceased JP2001500893A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus
SE9603533-2 1996-09-27
PCT/GB1997/002627 WO1998013384A1 (en) 1996-09-27 1997-09-26 Insulin c-peptides

Publications (2)

Publication Number Publication Date
JP2001500893A true JP2001500893A (ja) 2001-01-23
JP2001500893A5 JP2001500893A5 (enExample) 2005-05-12

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10515410A Ceased JP2001500893A (ja) 1996-09-27 1997-09-26 インスリンｃ―ペプチド

Country Status (24)

Country Link
US (1) US6610649B2 (enExample)
EP (1) EP0938503B1 (enExample)
JP (1) JP2001500893A (enExample)
KR (1) KR20000048643A (enExample)
AT (1) ATE347562T1 (enExample)
AU (1) AU741901B2 (enExample)
BG (1) BG103362A (enExample)
BR (1) BR9711573A (enExample)
CA (1) CA2266416C (enExample)
CZ (1) CZ108599A3 (enExample)
DE (1) DE69737065T2 (enExample)
DK (1) DK0938503T3 (enExample)
ES (1) ES2278394T3 (enExample)
HU (1) HUP0000432A3 (enExample)
IL (1) IL129143A0 (enExample)
IS (1) IS5008A (enExample)
NO (1) NO991483L (enExample)
NZ (1) NZ335231A (enExample)
PL (1) PL332494A1 (enExample)
RU (1) RU2206336C2 (enExample)
SE (1) SE520392C2 (enExample)
SK (1) SK39499A3 (enExample)
TR (1) TR199900694T2 (enExample)
WO (1) WO1998013384A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) * 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7384914B2 (en) * 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
EP1753446A4 (en) * 2004-05-27 2009-10-28 Essential Skincare Llc ALPHA-1 GLYCOPROTEIN ACID FOR THE TREATMENT OF DIABETES
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
WO2008019368A2 (en) * 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2009046851A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Cgrp as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
ES2927977T3 (es) 2017-02-06 2022-11-14 Biotempt Bv Moduladores peptídicos de la interacción entre el péptido C humano y el receptor de elastina humana para uso terapéutico

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166913B (enExample) * 1972-05-15 1975-06-28
JPS5210872B2 (enExample) 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
IL66611A0 (en) 1981-08-27 1982-12-31 Lilly Co Eli Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
DE69327239T2 (de) 1992-04-13 2000-05-11 Oklahoma Med Res Found Methoden and reagentien zur diagnose von autoantikörpern
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
MX9700198A (es) 1994-07-08 1997-04-30 Dartmouth College Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
CO4600637A1 (es) 1996-03-15 1998-05-08 Corixa Corp Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Also Published As

Publication number Publication date
IS5008A (is) 1999-03-23
AU741901B2 (en) 2001-12-13
AU4391597A (en) 1998-04-17
CZ108599A3 (cs) 1999-08-11
HUP0000432A2 (hu) 2000-08-28
EP0938503A1 (en) 1999-09-01
RU2206336C2 (ru) 2003-06-20
TR199900694T2 (xx) 1999-06-21
SK39499A3 (en) 1999-10-08
SE520392C2 (sv) 2003-07-01
WO1998013384A1 (en) 1998-04-02
SE9603533L (sv) 1998-03-28
BR9711573A (pt) 2000-01-18
DE69737065T2 (de) 2007-06-28
CA2266416A1 (en) 1998-04-02
KR20000048643A (ko) 2000-07-25
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
US20020107175A1 (en) 2002-08-08
US6610649B2 (en) 2003-08-26
HUP0000432A3 (en) 2000-10-30
SE9603533D0 (sv) 1996-09-27
EP0938503B1 (en) 2006-12-06
IL129143A0 (en) 2000-02-17
ATE347562T1 (de) 2006-12-15
ES2278394T3 (es) 2007-08-01
PL332494A1 (en) 1999-09-13
NO991483D0 (no) 1999-03-26
NO991483L (no) 1999-05-18
NZ335231A (en) 2000-11-24
BG103362A (en) 2000-05-31
DK0938503T3 (da) 2007-04-10

Similar Documents

Publication Publication Date Title
RU2206336C2 (ru) Фрагмент с-пептида человеческого проинсулина
AU634954B2 (en) Treatment of diabetes mellitus
US5939387A (en) Method of treating insulin resistance
CN103476933B (zh) 白介素1受体的拮抗剂
EP2683393B1 (en) Tripeptide compositions and their use for treatment of diabetes
JP2003523366A (ja) グルカゴン様ペプチド１化合物の可溶化方法
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
EP3157949A1 (en) Exendin-4 derivatives as selective glucagon receptor agonists
CA2686803A1 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
JP2819467B2 (ja) 新規なカルジオジラチン断片およびその製造方法
WO2003035099A1 (en) Biphasic mixtures of glp-1 and insulin
AU2010283169B2 (en) Novel peptide and use thereof
JP2026506334A (ja) Ｎｍｕ受容体２アゴニスト
JP5878922B2 (ja) 糖尿病血管合併症の治療
JP2002500161A (ja) 神経栄養性および鎮痛性のレトロインバースペプチド
WO2018188565A1 (zh) 用于治疗代谢系统疾病的多肽及其组合物
RU2317097C2 (ru) Гетерокарпин, белок растительного происхождения, обладающий противораковыми свойствами
EP3787661B1 (en) Combination of temozolomide and a par-1 conjugate for treating glioblastoma
US20120238490A1 (en) Methods and compositions for the treatment of metabolic disorders
WO2025123051A1 (en) Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain
MXPA99002734A (en) Insulin c-peptides
EP3842449A1 (en) Stapled olefin co-agonists of the glucagon and glp-1 receptors
HK1193563A (en) Tripeptide compositions and their use for treatment of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070827

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20071128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080115